Do Not Do Recommendation

 
First-line treatment in children and young people with benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome or late-onset childhood occipital epilepsy (Gastaut type) Levetiracetam is not cost effective at June 2011 unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least 50% of June 2011 value documented in the National Health Service Drug Tariff for England and Wales) if carbamazepine and lamotrigine are unsuitable or not tolerated

Do Not Do Recommendation Details

Recommendation:
First-line treatment in children and young people with benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome or late-onset childhood occipital epilepsy (Gastaut type) Levetiracetam is not cost effective at June 2011 unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least 50% of June 2011 value documented in the National Health Service Drug Tariff for England and Wales) if carbamazepine and lamotrigine are unsuitable or not tolerated
Interventions:
Levetiracetam

Source guidance details

Guidance:
Epilepsy (CG137)
Published date:
January 2012
Paragraph number:
1.9.11.3
Page number:
32

View all NICE do not do from this Guidance